Onconova Therapeutics Stock Price, News & Analysis (NASDAQ:ONTX) $0.70 +0.01 (+1.45%) (As of 12/1/2023 ET) Add Compare Share Share Today's Range$0.69▼$0.7050-Day Range$0.62▼$0.7452-Week Range$0.55▼$1.49Volume40,313 shsAverage Volume51,270 shsMarket Capitalization$14.69 millionP/E RatioN/ADividend YieldN/APrice Target$11.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Onconova Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,472.8% Upside$11.00 Price TargetShort InterestHealthy0.41% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.87Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.94) to ($0.72) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.94 out of 5 starsMedical Sector729th out of 951 stocksPharmaceutical Preparations Industry336th out of 431 stocks 3.5 Analyst's Opinion Consensus RatingOnconova Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $11.00, Onconova Therapeutics has a forecasted upside of 1,472.8% from its current price of $0.70.Amount of Analyst CoverageOnconova Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.41% of the outstanding shares of Onconova Therapeutics have been sold short.Short Interest Ratio / Days to CoverOnconova Therapeutics has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Onconova Therapeutics has recently increased by 21.10%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldOnconova Therapeutics does not currently pay a dividend.Dividend GrowthOnconova Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ONTX. Previous Next 2.7 News and Social Media Coverage News SentimentOnconova Therapeutics has a news sentiment score of 0.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Onconova Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for ONTX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Onconova Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.30% of the stock of Onconova Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 8.85% of the stock of Onconova Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Onconova Therapeutics are expected to grow in the coming year, from ($0.94) to ($0.72) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Onconova Therapeutics is -0.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Onconova Therapeutics is -0.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOnconova Therapeutics has a P/B Ratio of 1.01. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Onconova Therapeutics Stock (NASDAQ:ONTX)Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer in the United States. It has two clinical-stage programs, including narazaciclib, a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa study for the treatment of progressive K-Ras mutated non-small cell lung cancer. The company also conducting a Phase II investigator-initiated study with rigosertib monotherapy in patients with advanced/metastatic squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa. It has a license and collaboration agreement with HanX Biopharmaceuticals, Inc. for the development, registration, and commercialization of narazaciclib in China. Onconova Therapeutics, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.Read More ONTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ONTX Stock News HeadlinesNovember 28, 2023 | finance.yahoo.comOnconova Therapeutics to Present at NobleCon19, Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity ConferenceNovember 24, 2023 | americanbankingnews.comOnconova Therapeutics (NASDAQ:ONTX) Receives New Coverage from Analysts at StockNews.comDecember 3, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.November 16, 2023 | finance.yahoo.comOnconova Therapeutics, Inc. (NASDAQ:ONTX) Q3 2023 Earnings Call TranscriptNovember 16, 2023 | finanznachrichten.deOnconova Therapeutics, Inc.: Onconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial ResultsNovember 14, 2023 | finance.yahoo.comOnconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial ResultsNovember 7, 2023 | finance.yahoo.comOnconova Therapeutics to Provide Corporate Update and Announce Third Quarter 2023 Financial Results on November 14, 2023November 2, 2023 | benzinga.comOnconova Therapeutics' ASH Poster To Focus on Narazaciclib in MCLDecember 3, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.November 2, 2023 | finance.yahoo.comOnconova Therapeutics’ ASH Poster To Focus on Narazaciclib in MCLOctober 19, 2023 | markets.businessinsider.comPromising Developments in Onconova Therapeutics’ Drug Narazaciclib Bolster Buy Rating: An AnalysisOctober 19, 2023 | finance.yahoo.comPromising Preclinical Narazaciclib Data Presented at MCL MeetingOctober 12, 2023 | marketwatch.comOnconova Therapeutics Shares Rise 12% On Skin Cancer Treatment DataOctober 12, 2023 | finance.yahoo.comEncouraging Rigosertib Data Presented at EADV as Late BreakerSeptember 28, 2023 | finance.yahoo.comOnconova Therapeutics to Present a Late-Breaking Abstract on Rigosertib at the 2023 EADV CongressSeptember 6, 2023 | finance.yahoo.comOnconova Therapeutics to Participate at the H.C. Wainwright 25th Annual Global Investment ConferenceAugust 11, 2023 | markets.businessinsider.comH.C. Wainwright Sticks to Their Buy Rating for Onconova Therapeutics (ONTX)August 11, 2023 | finance.yahoo.comQ2 2023 Onconova Therapeutics Inc Earnings CallAugust 10, 2023 | finance.yahoo.comOnconova Therapeutics Reports Corporate Update and Announces Second Quarter 2023 Financial ResultsAugust 3, 2023 | finance.yahoo.comOnconova Therapeutics to Provide Corporate Update and Announce Second Quarter 2023 Financial Results on August 10, 2023July 17, 2023 | finance.yahoo.comHere's Why We're Watching Onconova Therapeutics' (NASDAQ:ONTX) Cash Burn SituationJune 14, 2023 | finance.yahoo.comOnconova Therapeutics Presents Preclinical Data on Narazaciclib at the 17th International Conference on Malignant LymphomaJune 7, 2023 | msn.comHC Wainwright & Co. Reiterates Onconova Therapeutics (ONTX) Prior RecommendationJune 6, 2023 | markets.businessinsider.comOnconova Therapeutics (ONTX) Receives a Buy from H.C. WainwrightJune 5, 2023 | finance.yahoo.comOnconova Therapeutics Announces Poster Presentation at the American Society of Clinical Oncology Annual MeetingMay 25, 2023 | finance.yahoo.comOnconova Therapeutics Announces Dosing of First Participant in Investigator-Sponsored Phase 2 Trial of Rigosertib Plus Pembrolizumab in Metastatic Melanoma Patients Refractory to Immune Checkpoint BlockadeMay 17, 2023 | marketwatch.com8-K: Onconova Therapeutics, Inc.See More Headlines Receive ONTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Onconova Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/11/2021Today12/03/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/21/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ONTX CUSIPN/A CIK1130598 Webwww.onconova.com Phone(267) 759-3680Fax267-759-3681Employees16Year FoundedN/APrice Target and Rating Average Stock Price Target$11.00 High Stock Price Target$11.00 Low Stock Price Target$11.00 Potential Upside/Downside+1,472.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.97) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-18,960,000.00 Net Margins-8,930.97% Pretax Margin-8,930.97% Return on Equity-95.43% Return on Assets-61.19% Debt Debt-to-Equity RatioN/A Current Ratio2.79 Quick Ratio2.79 Sales & Book Value Annual Sales$226,000.00 Price / Sales65.00 Cash FlowN/A Price / Cash FlowN/A Book Value$0.69 per share Price / Book1.01Miscellaneous Outstanding Shares21,003,000Free Float20,310,000Market Cap$14.69 million OptionableNot Optionable Beta1.70 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesDr. Steven M. Fruchtman M.D. (Age 72)CEO, President & Director Comp: $907.86kMr. Mark Patrick Guerin CPA (Age 54)CFO & COO Comp: $629.27kDr. Adar Makovski Silverstein Ph.D.Senior Director & Head of Corporate DevelopmentDr. Victor Moyo M.D.Chief Medical OfficerKey CompetitorsVBI VaccinesNASDAQ:VBIVImpel PharmaceuticalsNASDAQ:IMPLOrgenesisNASDAQ:ORGSLandos BiopharmaNASDAQ:LABPAgeX TherapeuticsNYSE:AGEView All Competitors ONTX Stock Analysis - Frequently Asked Questions Should I buy or sell Onconova Therapeutics stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Onconova Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ONTX shares. View ONTX analyst ratings or view top-rated stocks. What is Onconova Therapeutics' stock price target for 2024? 1 brokerages have issued 12-month price objectives for Onconova Therapeutics' stock. Their ONTX share price targets range from $11.00 to $11.00. On average, they predict the company's stock price to reach $11.00 in the next twelve months. This suggests a possible upside of 1,472.8% from the stock's current price. View analysts price targets for ONTX or view top-rated stocks among Wall Street analysts. How have ONTX shares performed in 2023? Onconova Therapeutics' stock was trading at $0.6457 on January 1st, 2023. Since then, ONTX stock has increased by 8.3% and is now trading at $0.6994. View the best growth stocks for 2023 here. Are investors shorting Onconova Therapeutics? Onconova Therapeutics saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 85,500 shares, an increase of 21.1% from the October 31st total of 70,600 shares. Based on an average daily trading volume, of 70,800 shares, the short-interest ratio is currently 1.2 days. View Onconova Therapeutics' Short Interest. When is Onconova Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 21st 2024. View our ONTX earnings forecast. How were Onconova Therapeutics' earnings last quarter? Onconova Therapeutics, Inc. (NASDAQ:ONTX) released its earnings results on Thursday, November, 11th. The biopharmaceutical company reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($0.33) by $0.11. The biopharmaceutical company had revenue of $0.06 million for the quarter, compared to the consensus estimate of $0.06 million. Onconova Therapeutics had a negative net margin of 8,930.97% and a negative trailing twelve-month return on equity of 95.43%. During the same quarter in the previous year, the business earned ($0.45) EPS. When did Onconova Therapeutics' stock split? Shares of Onconova Therapeutics reverse split before market open on Friday, May 21st 2021. The 1-15 reverse split was announced on Thursday, May 20th 2021. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 20th 2021. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. What other stocks do shareholders of Onconova Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Onconova Therapeutics investors own include Sorrento Therapeutics (SRNE), OPKO Health (OPK), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Tonix Pharmaceuticals (TNXP), Acasti Pharma (ACST), Bionano Genomics (BNGO), Matinas BioPharma (MTNB), Outlook Therapeutics (OTLK) and Actinium Pharmaceuticals (ATNM). Who are Onconova Therapeutics' major shareholders? Onconova Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Abraham N Oler, Abraham N Oler, James J Marino, Mark Patrick Guerin and Steven M Fruchtman. View institutional ownership trends. How do I buy shares of Onconova Therapeutics? Shares of ONTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:ONTX) was last updated on 12/3/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Onconova Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.